936901-74-5

Usage

Uses

Used in Medicinal Chemistry:
(1s,3s)-3-(8-Bromo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)-1-methylcyclobutanol is used as a compound in medicinal chemistry for its potential to interact with biological targets, which could lead to the development of new drugs and therapies.
Used in Drug Discovery:
In the field of drug discovery, (1s,3s)-3-(8-Bromo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)-1-methylcyclobutanol is utilized for its unique structure and potential pharmacological properties, which may contribute to the identification of novel therapeutic agents.
Used in Scientific Research:
(1s,3s)-3-(8-Bromo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)-1-methylcyclobutanol serves as a valuable tool in scientific research, where its synthesis and characterization can provide insights into the development of new organic compounds and their applications.
Used in Organic Chemistry:
In the realm of organic chemistry, (1s,3s)-3-(8-Bromo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)-1-methylcyclobutanol is of interest to chemists and researchers for its synthesis and potential as a building block for the creation of new complex organic molecules.

Upstream product

• 936901-73-4 3-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone 
• 75-16-1 methylmagnesium bromide 
• 676-58-4 methylmagnesium chloride 

Downstream Products

• 936901-75-6 cis-3-(8-amino-1-bromo-imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol 
• 1356958-93-4 cis-8-amino-3-(3-hydroxy-3-methyl-cyclobutyl)-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-7-ium methanesulfonate 
• 1356958-77-4 cis-8-amino-3-(3-hydroxy-3-methyl-cyclobutyl)-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-7-ium chloride 

Relevant academic research and scientific papers

Discovery of potent, selective and orally bioavailable imidazo[1,5-a] pyrazine derived ACK1 inhibitors

This Letter describes the medicinal chemistry effort towards a series of novel imidazo[1,5-a]pyrazine derived inhibitors of ACK1. Virtual screening led to the discovery of the initial hit, and subsequent exploration of structure-activity relationships and

PROCESS FOR THE PREPARATION OF THE COMPOUND OSI - 906

Process for preparing the tyrosine kinase inhibitor OSI-906 comprises coupling Compound (2) with Compound (6) under specified conditions.

Fused bicyclic mTOR inhibitors

Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.

Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors

The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA?).